Testosterone (Cypionate, Enanthate, and Gel Pump) Coverage Criteria
Customize your policy alerts
Sign up for all hennepinhealth policy alerts
Know when hennepinhealth releases new policies or updates existing guidance.
Monitor payer policy activity
Prior authorization and coverage criteria for testosterone cypionate, testosterone enanthate, and testosterone gel pumps for members of Hennepin Health, including indications of gender dysphoria and hypogonadism.
No material clinical or coverage changes in this revision.
Coverage Criteria
inv-01: Gender dysphoria — Initial Approval
Covered when ALL of the following are met:
Documentation of the diagnosis must be provided with the request.
If the member has a documented contraindication to testosterone cypionate, note the contraindication in the request.
inv-02: Hypogonadism — Initial Approval
Covered when ALL of the following are met:
Both tests must be documented and dated; tests must be within the 18-month look-back period.
If contraindication to cypionate is claimed, documentation must be provided.
This policy sets forth coverage criteria for testosterone formulations used to treat hypogonadism and gender‑affirming therapy. There are no additional explicit exclusion conditions listed in the policy beyond the clinical criteria and requirements described for each indication. Providers should follow the specific diagnosis, laboratory, and step‑therapy requirements in the applicable sections to determine medical necessity and prior authorization needs.
Key Clinical Thresholds & Coding
Provider Actions & Authorization Requirements
Prior authorization required for listed testosterone formulations
Prior authorization is required for testosterone cypionate, testosterone enanthate, and testosterone gel pumps before coverage will be considered.
Step therapy and trial requirements
Certain formulations require documented trials or a documented contraindication to the preferred product before approval.
- Testosterone enanthate requires a trial of testosterone cypionate unless contraindicated.
- Testosterone gel pump 1% requires a trial of testosterone gel pump 1.62%.
- Testosterone gel pump 1.62% and testosterone cypionate do not require step therapy.
Formulation-specific step therapy rules
Follow formulation-specific step therapy: enanthate requires prior trial of cypionate; gel pump 1% requires prior trial of gel pump 1.62%; no trial is required for gel pump 1.62% or cypionate.
- Testosterone enanthate: trial of testosterone cypionate required unless contraindicated.
- Testosterone gel pump 1%: trial of testosterone gel pump 1.62% required.
- No step therapy required for testosterone gel pump 1.62% or testosterone cypionate.
Provide two early-morning testosterone levels within 18 months
For hypogonadism approval submit two early-morning (before 10 a.m.) total testosterone levels obtained within the past 18 months showing low testosterone (<300 ng/dL).
- Two AM testosterone measurements (before 10 a.m.).
- Both results must be <300 ng/dL.
- Both tests must be within the past 18 months.
Document diagnosis of gender dysphoria when applicable
When the request is for treatment of gender dysphoria, include documentation of the member's diagnosis of gender dysphoria in the prior authorization submission.
Denial triggers for missing PA or unmet clinical criteria
Coverage may be denied if there is no prior authorization or if the clinical criteria (diagnosis, required laboratory documentation, or required step-therapy trials) are not met.
- No prior authorization on file for testosterone cypionate, enanthate, or gel pump.
- Missing required diagnosis (gender dysphoria or qualifying hypogonadism).
- Missing two early-morning testosterone levels <300 ng/dL within 18 months for hypogonadism.
- Failure to document required step-therapy trials or contraindications (e.g., enanthate without prior cypionate trial).
Background
This policy addresses use of testosterone products for members with primary hypogonadism, hypogonadotropic hypogonadism, and for gender‑affirming hormone therapy when a diagnosis of gender dysphoria is documented. For hypogonadism, coverage requires two early‑morning (before 10 a.m.) total testosterone measurements showing <300 ng/dL obtained within the past 18 months. Formulation‑specific step therapy rules apply: testosterone gel pump 1.62% and testosterone cypionate do not require step therapy; testosterone enanthate requires a trial of testosterone cypionate unless contraindicated; and testosterone gel pump 1% requires a trial of testosterone gel pump 1.62%. Prior authorization is required for the listed products and approval is contingent on meeting these documentation and trial requirements.
Definitions
Initial Therapy Criteria
inv-15: Initial therapy step requirements
Formulation-specific initial therapy and trial requirements:
These products may be approved without prior trial of other listed formulations.
Documentation of the prior trial or contraindication must be included with the authorization request.
Document dates and outcomes of prior trial of gel pump 1.62%.
Step Therapy Table
| Formulation | Step therapy / trial requirement |
|---|---|
| Testosterone enanthate | Requires prior trial of testosterone cypionate unless contraindicated. |
| Testosterone cypionate | Does not require step therapy (preferred initial formulation). |
| Testosterone gel pump 1.62% | Does not require step therapy (can be used prior to other gel pump strengths). |
| Testosterone gel pump 1% | Requires prior trial of testosterone gel pump 1.62%. |
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.